In their editorial, Walter and Clements advised caution before switching to a reduced-dose schedule, noting that the majority of cost savings for PCV are related to reductions in costs for treating very frequently occurring infections, such as otitis media, rather than less commonly occurring but more serious life-threatening invasive pneumococcal disease.